Brett Hagen - Apr 10, 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Chief Accounting Officer
Signature
/s/ Brett Hagen
Stock symbol
KLRS
Transactions as of
Apr 10, 2025
Transactions value $
$0
Form type
4
Date filed
4/11/2025, 05:27 PM
Previous filing
Mar 27, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +50.3K $0.00 50.3K Apr 10, 2025 Common Stock 50.3K $7.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.